公开(公告)号：US20110196274A1

公开(公告)日：2011-08-11

申请号：US12702931

申请日：2010-02-09

Applicant: Jane Ding ,  Yu Bo Ding

Inventor： Jane Ding ,  Yu Bo Ding

IPC: A61H7/00

CPC classification number: A61H15/0078 ,  A61H7/007 ,  A61H2007/009 ,  A61H2201/0134 ,  A61H2201/1215 ,  A61H2201/1654

Abstract: A massager system includes one or more gear trains coupled to a motor to rotate at least a pair of shafts that each supports a pair of nodules for rotation about the associated shaft. A pillow-shaped outer housing surrounds the motor and number of coupled gear trains with the nodules protruding above the outer housing to facilitate contact with a selected bodily region to knead or otherwise stimulate surface skin in a bodily region.

Abstract translation: 按摩器系统包括耦合到电动机的一个或多个齿轮系，以旋转至少一对轴，每个轴支撑一对结节以围绕相关联的轴旋转。 围绕电动机的枕形外壳和配合齿轮系的数量，其中结节突出在外壳上方，以便于与选定的身体区域接触以揉合或以其他方式刺激身体区域中的表皮。

公开(公告)号：US10342806B2

公开(公告)日：2019-07-09

申请号：US15196878

申请日：2016-06-29

Applicant: Robert Dana Frisina ,  Joseph Paul Walton ,  Bo Ding ,  Xiaoxia Zhu

Inventor： Robert Dana Frisina ,  Joseph Paul Walton ,  Bo Ding ,  Xiaoxia Zhu

IPC: A61K31/573 ,  A61K45/06 ,  A61K31/616 ,  A61K31/192 ,  A61K33/02

Abstract: Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems. When given in the proper dosage the compounds have few, if any side effects, and initial evidence supports the effectiveness of the drug from in vitro experiments, and in vivo studies of aging mice, indicating is usefulness in preventing/treating one of the most pervasive forms of permanent hearing loss.

公开(公告)号：US08282585B2

公开(公告)日：2012-10-09

申请号：US12702931

申请日：2010-02-09

Applicant: Jane Ding ,  Yu Bo Ding

Inventor： Jane Ding ,  Yu Bo Ding

IPC: A61H7/00

CPC classification number: A61H15/0078 ,  A61H7/007 ,  A61H2007/009 ,  A61H2201/0134 ,  A61H2201/1215 ,  A61H2201/1654

Abstract: A massager system includes one or more gear trains coupled to a motor to rotate at least a pair of shafts that each supports a pair of nodules for rotation about the associated shaft. A pillow-shaped outer housing surrounds the motor and number of coupled gear trains with the nodules protruding above the outer housing to facilitate contact with a selected bodily region to knead or otherwise stimulate surface skin in a bodily region.

Abstract translation: 按摩器系统包括耦合到电动机的一个或多个齿轮系，以旋转至少一对轴，每个轴支撑一对结节以围绕相关联的轴旋转。 围绕电动机的枕形外壳和配合齿轮系的数量，其中结节突出在外壳上方，以便于与选定的身体区域接触以揉合或以其他方式刺激身体区域中的表皮。

公开(公告)号：US20120036252A1

公开(公告)日：2012-02-09

申请号：US12967614

申请日：2010-12-14

Applicant: Dianxi Shi ,  Wei Zhang ,  Huaimin Wang ,  Bo Ding ,  Hui Liu ,  Gang Yin ,  Meng Teng ,  Yongzhi Yang ,  Xiang Rao

Inventor： Dianxi Shi ,  Wei Zhang ,  Huaimin Wang ,  Bo Ding ,  Hui Liu ,  Gang Yin ,  Meng Teng ,  Yongzhi Yang ,  Xiang Rao

IPC: G06F15/173

CPC classification number: H04L67/16 ,  G06F9/5055 ,  H04L12/2809

Abstract: The present invention provides an OSGi-based heterogeneous service integrating system comprising a Java virtual machine and an OSGi container, the system further comprises a service management module, a handler management module, a monitor module, a service discovery module and a handler module that are running on said OSGi container, wherein: said service management module is adapted to monitor requests for registering and using of a remote service, to manage different types of services, and to notify said handler management module to make corresponding publishing and calling for different service configuration types; said handler management module is adapted to manage said handler module and to publish service to and call service from remote end points, and to call the corresponding handler module based on information delivered by the service management module, and to maintain information of currently published services and adopted remote services; said monitor module is adapted to monitor a local service registry in said OSGi container and to obtain information to be monitored from the service management module; said service discovery module is adapted to make remote service discovery; and said handler module is adapted to realize access of a module within the OSGi container to a service outside the OSGi container.

Abstract translation: 本发明提供了一种基于OSGi的异构服务集成系统，其包括Java虚拟机和OSGi容器，该系统还包括服务管理模块，处理程序管理模块，监视器模块，服务发现模块和处理程序模块， 在所述OSGi容器上运行，其中：所述服务管理模块适于监视对远程服务的注册和使用的请求，以管理不同类型的服务，并且通知所述处理程序管理模块进行相应的发布和呼叫不同的服务配置 类型 所述处理程序管理模块适于管理所述处理程序模块，并将服务发布到远程端点并从其呼叫服务，并根据服务管理模块提供的信息调用相应的处理程序模块，并维护当前发布的服务的信息， 采用远程服务; 所述监视器模块适于监视所述OSGi容器中的本地服务注册表，并从所述服务管理模块获取要监视的信息; 所述服务发现模块适于进行远程服务发现; 并且所述处理器模块适于实现OSGi容器内的模块到OSGi容器外部的服务的访问。

公开(公告)号：US10757342B1

公开(公告)日：2020-08-25

申请号：US15962314

申请日：2018-04-25

Applicant: Bo Ding ,  Dmitry Ryuma

Inventor： Bo Ding ,  Dmitry Ryuma

IPC: H04N5/235 ,  G03B17/48 ,  G03B7/093 ,  G02B27/01

Abstract: An auto exposure method for an image capture device includes the steps of gathering ambient light data using an ambient light sensor of the image capture device, selecting a frame rate corresponding to the gathered ambient light data, and determining an optimal image capture frame rate for the image capture device. The auto exposure method determines the optimal image capture frame rate by executing an auto exposure algorithm with a processor using the selected frame rate as an initialization parameter for the auto exposure algorithm.

公开(公告)号：US20160375038A1

公开(公告)日：2016-12-29

申请号：US15196878

申请日：2016-06-29

Applicant: Robert Dana Frisina ,  Joseph Paul Walton ,  Bo Ding ,  Xiaoxia Zhu

Inventor： Robert Dana Frisina ,  Joseph Paul Walton ,  Bo Ding ,  Xiaoxia Zhu

IPC: A61K31/573 ,  A61K33/02 ,  A61K31/192 ,  A61K45/06 ,  A61K31/616

CPC classification number: A61K31/573 ,  A61K31/192 ,  A61K31/616 ,  A61K33/02 ,  A61K45/06 ,  A61K2300/00

Abstract: Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems. When given in the proper dosage the compounds have few, if any side effects, and initial evidence supports the effectiveness of the drug from in vitro experiments, and in vivo studies of aging mice, indicating is usefulness in preventing/treating one of the most pervasive forms of permanent hearing loss.

Abstract translation: 永久性听力损失或耳聋影响全球约15％的人，仅在美国约4000万人。 目前美国市场上没有FDA批准的药物，或世界上任何防止，治疗或逆转永久性听力损失或耳聋的药物。 年龄相关性听力损失（ARHL）是永久性听力损失和耳聋的最常见形式之一。 ARHL是我们老年人口的第一大神经退行性疾病，＃1通讯障碍和前3名慢性疾病（以及关节炎和心血管疾病）中的1种。 ARHL的发病率正在上升，因为“婴儿潮一代”达到老年，并且一生的噪音暴露的累积效应，以及广泛使用的具有耳毒性或具有耳毒性副作用的化学治疗和抗生素药物。 披露了一种新药物，以防止或减缓ARHL的进展，这是基于市场上现有的自然FDA批准的化合物，用于治疗其他非ARHL生物医学问题。 当以适当剂量给予时，化合物几乎没有任何副作用，并且初步证据支持药物从体外实验的有效性和老化小鼠的体内研究，表明在预防/治疗最普遍的一种中是有用的 永久性听力损失形式。

公开(公告)号：USD666303S1

公开(公告)日：2012-08-28

申请号：US29357053

申请日：2010-03-05

Applicant: Jane Jian Ding ,  Yu Bo Ding

Designer： Jane Jian Ding ,  Yu Bo Ding